Grifols (NASDAQ:GRFS) Price Target Lowered to €10.30 at JPMorgan Chase & Co.

Grifols (NASDAQ:GRFSGet Rating) had its price target decreased by JPMorgan Chase & Co. from €11.50 ($11.73) to €10.30 ($10.51) in a research report released on Wednesday, The Fly reports.

A number of other equities analysts have also commented on GRFS. Jefferies Financial Group assumed coverage on shares of Grifols in a research report on Monday, July 25th. They issued a hold rating for the company. Berenberg Bank raised their target price on shares of Grifols from €20.15 ($20.56) to €20.30 ($20.71) and gave the company a buy rating in a research note on Friday, July 15th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on shares of Grifols from €17.00 ($17.35) to €16.00 ($16.33) and set a hold rating on the stock in a research note on Tuesday, August 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of Hold and a consensus price target of $15.53.

Grifols Stock Down 3.1 %

GRFS stock opened at $8.24 on Wednesday. The firm has a 50 day moving average of $9.05 and a 200-day moving average of $10.81. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.91 and a current ratio of 2.68. Grifols has a 12 month low of $7.39 and a 12 month high of $15.90.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in shares of Grifols during the first quarter worth approximately $2,907,000. Bank of Montreal Can raised its stake in shares of Grifols by 123.0% during the fourth quarter. Bank of Montreal Can now owns 172,187 shares of the biotechnology company’s stock worth $1,959,000 after acquiring an additional 94,983 shares in the last quarter. Oppenheimer Asset Management Inc. raised its stake in shares of Grifols by 43.1% during the first quarter. Oppenheimer Asset Management Inc. now owns 43,233 shares of the biotechnology company’s stock worth $505,000 after acquiring an additional 13,028 shares in the last quarter. Ridgewood Investments LLC raised its stake in shares of Grifols by 2.9% during the first quarter. Ridgewood Investments LLC now owns 58,844 shares of the biotechnology company’s stock worth $687,000 after acquiring an additional 1,680 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of Grifols during the fourth quarter worth approximately $1,587,000. 14.62% of the stock is owned by hedge funds and other institutional investors.

About Grifols

(Get Rating)

Grifols, SA engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.

See Also

The Fly logo

Analyst Recommendations for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.